Although rarely used in the US, it may be time to revisit HRT for women with MS, as it eases overlapping symptoms and offers a justifiable benefit-risk profile, experts say.

BRAFTOVI regimen showed a 51% reduced risk of death vs. standard chemo (HR 0.49). Median survival with BRAFTOVI combo reached 30.3 months vs. 15.1 months for chemo. Rebound or breakdown? See how ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Um Unternehmen dabei zu unterstützen, den immer strengeren Datenschutzbestimmungen einen Schritt voraus zu sein, hat Regula, ein globaler Entwickler von Identitätsprüfungslösungen, seine ...

Find detailed listings for mental health professionals in: United States United States ...

Cooper G and Tomanek R (1982) Load regulation of the structure, composition, and function of mammalian myocardium., Circulation Research, 50:6, (788-798), Online publication date: 1-Jun-1982. Chilian ...

An assessment of their significance in the absence of valvar stenosis., Heart, 10.1136/hrt.53.6.640, 53:6, (640-644), Online publication date: 1-Jun-1985. NISHIMURA R , MILLER F , CALLAHAN M , BENASSI ...